Sandra Twyman Twyman

GPSG Training Coordinator at Centocor - , N/A, US

Sandra Twyman Twyman's Colleagues at Centocor
Bernard Amegadzie

Director, Strategic External R&D- Biologics

Contact Bernard Amegadzie

Donald Rossi

Sr. System Support Manager

Contact Donald Rossi

Paul Kunko

Senior Manager, Business Analytics

Contact Paul Kunko

Craig Cathcart

Promotional Operations Coordinator

Contact Craig Cathcart

View All Sandra Twyman Twyman's Colleagues
Sandra Twyman Twyman's Contact Details
HQ
610-651-6000
Location
Malvern, Pennsylvania, United States
Company
Centocor
Sandra Twyman Twyman's Company Details
Centocor logo, Centocor contact details

Centocor

, N/A, US • 1000 - 4999 Employees
BioTech/Drugs

Subsidiary of Johnson & Johnson, Centocor is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal antibody technology.In 1982 Centocor developed their first product approved by the U.S. Food and Drug Administration (FDA) — a diagnostic test used to detect the rabies virus, and in that same year transitioned into a publicly traded company. Subsequently, the company moved to a larger facility in Malvern, Pennsylvania (a northwest suburb of Philadelphia). In 1984, Centocor opened an overseas plant in Leiden, the Netherlands.Eighteen years after its foundation, (in 1997), Centocor achieved its first year of operating profitability. In 1998, Centocor divested itself of its diagnostic division and launched its top-selling monoclonal antibody Remicade (infliximab) for its first FDA approved indication in Crohn's Disease. In 1999, Centocor became a wholly owned subsidiary of Johnson & Johnson, the worldwide manufacturer and marketer of healthcare products. Subsequently, Remicade's market has expanded with approvals for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and pediatric Crohn's disease. Remicade was approved for plaque psoriasis in September 2006.Centocor also markets ReoPro (abciximab), a biologic agent indicated as an adjunct to coronary angioplasty (PTCA).Since being acquired by Johnson and Johnson, Centocor has increased its annual sales from approximately $500 million to more than $2 billion. During the same period, research and development investment increased from $75 million to more than $300 million.In 2004 Centocor purchased a new manufacturing plant in St. Louis, Missouri, and is currently opening a new manufacturing facility in County Cork, Ireland. The Dutch plant has been expanded substantially with a $250 million investment in additional production facilities, which were opened in 2006.

BioTech/Drugs Commercial Physical Research Biotechnology
Details about Centocor
Frequently Asked Questions about Sandra Twyman Twyman
Sandra Twyman Twyman currently works for Centocor.
Sandra Twyman Twyman's role at Centocor is GPSG Training Coordinator.
Sandra Twyman Twyman's email address is ***@centocor.com. To view Sandra Twyman Twyman's full email address, please signup to ConnectPlex.
Sandra Twyman Twyman works in the BioTech/Drugs industry.
Sandra Twyman Twyman's colleagues at Centocor are Bernard Amegadzie, Donald Rossi, Begum Selima, Paul Kunko, Craig Cathcart, Chuck Pendley, Garreth Sharp and others.
Sandra Twyman Twyman's phone number is 610-651-6000
See more information about Sandra Twyman Twyman